SCHEMBL5846377

SCHEMBL5846377

COCOCc1cc(B(O)O)cc(-c2ccc3c(c2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RARG P13631 19/20 0.40
RARA P10276 10/20 0.40
RARB P10826 10/20 0.40
RXRA P19793 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5847919 0.82 RARG (0.39) RARGRARARARBRXRA
SCHEMBL5845449 0.80 RARG (0.63) RARGRARARARBRXRA
SCHEMBL5846465 0.77 RARG (0.56) RARGRARARARBRXRA
SCHEMBL5846381 0.74 RARA (0.40) RARGRARARARBRXRA
SCHEMBL26923655 0.73 RARB (0.54) RARGRARARARBRXRA
SCHEMBL5846235 0.72 RARG (0.50) RARGRARARARBRXRA
SCHEMBL5846349 0.67 RARG (0.44) RARGRARARARBRXRA
SCHEMBL2012286 0.66 RXRA (0.45) RARGRARARARBRXRA
SCHEMBL29893588 0.66 RXRA (0.45) RARGRARARARBRXRA
SCHEMBL5847673 0.65 RARB (0.58) RARGRARARARBRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148245-B2 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-12-12 US disclosed
US-20040030141-A1 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT 2004-02-12 US disclosed
US-6649612-B1 Combating skin ageing and keratinization GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-11-18 US disclosed
US-6316009-B1 FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN GALDERMA RESEARCH & DEVELOPMENT (FR) 2001-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040030141-A1 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them AHR, TYR, CYP1A1 RARG 39/4885RARA 24/4885RARB 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.